Thelansis

Presbyopia Emerging Therapy and TPP Insights Thelansis’s “Presbyopia Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Key business questions answered: Detailed emerging competitive landscape Pipeline analysis Target patients for emerging therapies Key companies Key mechanism of actions Launch date estimates, etc. Clinical trial landscape analysis Target patient segments Trial endpoints Trial design Recruitment criteria, etc. Unmet Needs and Opportunities Performance of key current therapies Top areas of unmet needs Opportunity sizing for key unmet needs Target Product Profiles Attributes and le...

Presbyopia Emerging Therapy and TPP Insights Thelansis’s “Presbyopia Emerging Therapy, with Unmet Needs and TPP Insights Report – 2024 To 2034″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Presbyopia Overview Presbyopia presents a widespread challenge affecting over a billion individuals globally. In developing regions, up to half of those aged 50 and above grapple with unmanaged presbyopia due to limited awareness and access to affordable treatment. Even in developed nations, the prevalence can reach as high as 34%. The definitions of presbyopia vary considerably, prompting a proposed redefinition: “Presbyopia arises when the natural age-related decline in the eye’s focusing ability reaches a point where, despite optimal correction for distance vision, near vision clarity fails ...